FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to substituted isoquinolines and isoquinolinones of formula (I) and to their stereoisomer and/or tautomer forms and/or pharmaceutically acceptable salts, wherein R1 is H, OH or NH2； R3 is H； R4 is H, halogen or (C1-C6)alkylene-R'； R5 is H, halogen, (C1-C6)alkyl； R7 is H, halogen, (C1-C6)alkyl, O-(C1-C6)alkyl； R8 is H； R6 is absent； or is one of (C1-C4)alkylene related to a cycloalkyl ring related to a cycloalkyl ring, wherein (C1-C4)alkylene forms a second bond to another carbon atom of the cycloalkyl ring to form a bicyclic ring system, R10 is H, phenyl, or pyridine, wherein phenyl is unsubstituted or substituted； R11 is H, (C1-C6)alkyl； or R11 and R12 together with the carbon atom to which they are attached form (C3)cycloalkyl； R12 is (C1-C6)alkyl, (C3-C8)cycloalkyl or phenyl； or R12 is H, provided r=2 and another R12 is other than H； or R11 and R12 together with the carbon atom to which they are attached form (C3)cycloalkyl； R13 and R14 are independently H, (C1-C6)alkyl, (C1-C6)alkylene-R', C(O)O-(C1-C6)alkyl, n is equal to 0； m is equal to 1 or 2； s is equal to 1 or 2； r is equal to 1 or 2； L is O, NH； R' is (C3-C8)cycloalkyl, (C6-C10)aryl； wherein in R11 and R12 residues, alkyl is unsubstituted or optionally substituted by one OCH3； wherein in R11 and R12 residues, alkyl is unsubstituted or optionally substituted by one or more halogens； wherein in R10 and R12 residues, (C6-C10)aryl is unsubstituted or optionally substituted by one or two groups optionally specified in halogen, CN, (C1-C6)alkyl, O-(C1-C6)alkyl, SO2-(C1-C6)alkyl, CF3 and OCF3. Also, the invention refers to using a compound of formula (I).EFFECT: there are prepared new isoquinoline and isoquinolinone derivatives effective in treating and preventing the diseases related to Rho-kinase inhibition.38 cl, 132 exИзобретение относится к замещенным изохинолинам и изохинолинонам формулы (I) и к их стереоизомерным и/или таутомерным формам и/или
